Anti-SARS-CoV-2 NTD Antibodies for Broad Variant Neutralization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The emergence of SARS-COV-2 variants of concern has led to increased transmissibility and reduced efficacy of existing therapeutics and vaccines due to mutations on the spike protein, necessitating the development of broadly neutralizing anti-SARS-COV-2 antibodies.
Innovation Solution
Development of anti-SARS-COV-2 antibodies or antigen-binding fragments that target specific epitopes on the spike protein, including the N-terminal domain and supersite b-hairpin, β8-strand, N4-loop, and N-linked glycans, with variable regions exhibiting at least 75% identity to specific sequences, capable of neutralizing multiple SARS-COV-2 strains.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapeutics and vaccines target the spike protein of SARS-COV-2, then they provide treatment and prevention capability, but variants of concern with mutations on the spike protein reduce their efficacy
Solution Approach 1:
The patent develops antibodies that target multiple epitopes on the spike protein (including the N-terminal domain and supersite b-hairpin), enabling a single therapeutic agent to neutralize multiple SARS-COV-2 variants of concern simultaneously, thus achieving universal protection against diverse viral strains
Solution Approach 2:
The invention focuses on targeting specific conserved regions of the spike protein (such as the N-terminal domain and supersite b-hairpin) that remain relatively unchanged across variants, rather than targeting variable regions. This localized targeting approach ensures maintained efficacy against emerging variants while preserving the antibody's neutralizing function
2Reliability
If antibodies target specific epitopes on the spike protein to achieve broad neutralization, then neutralization capability improves, but antibody design and production complexity increases
Solution Approach 1:
The patent identifies and targets distinct epitopic segments on the spike protein (N-terminal domain, supersite b-hairpin, β8-strand, N4-loop) separately, designing antibodies that bind to these discrete regions. This segmentation allows for modular antibody design where each antibody targets a specific epitope, simplifying the overall design process while achieving broad neutralization through combinatorial effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies demonstrate broad neutralization capability against various SARS-COV-2 strains, including variants of concern, and can be used for treatment and prevention of infection, with applications in diagnostic assays and therapeutic compositions.
Implementation Method 1
anti-SARS-COV-2 antibodies or antigen-binding fragments that bind specifically to a SARS-COV-2 antigen... binds specifically to a SARS-COV-2 antigen... targeting the n-terminal domain of the spike protein
Implementation Method 2
capable of neutralizing a plurality of SARS-COV-2 strains... broadly neutralizing anti-SARS-COV-2 antibodies for treating or preventing SARS-COV-2 infection
Data Source
AI summary
This disclosure provides anti-SARS-COV-2 antibodies or antigen-binding fragments thereof targeting the N-terminal domain (NTD) of the spike(S) protein. The disclosed anti-SARS-COV-2 antibodies or antigen-binding fragments thereof have broadly neutralizing activities against several SARS-COV-2 variants of concern. The disclosed anti-SARS-COV-2 antibodies represent a therapeutic strategy in protecting from SARS-COV-2 infections.